{"id":32805,"date":"2025-07-15T17:05:56","date_gmt":"2025-07-15T11:35:56","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32805"},"modified":"2025-07-15T17:05:57","modified_gmt":"2025-07-15T11:35:57","slug":"pharma-news-for-bayer-klotho-trethera","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera","title":{"rendered":"Nanoscope\u2019s MCO-010 Begins FDA Rolling Submission for Retinitis Pigmentosa; Bayer\u2019s KERENDIA Approved by FDA for Heart Failure With Preserved Ejection Fraction; Klotho Neurosciences\u2019 KLTO-202 Receives FDA Orphan Drug Designation for ALS; Trethera\u2019s TRE-515 Granted FDA Fast Track Designation for Metastatic Prostate Cancer; Adcentrx\u2019s ADRX-0405 Awarded FDA Orphan Drug Designation for Gastric Cancer"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69dec1b05e36e\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69dec1b05e36e\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera\/#Nanoscope_Therapeutics_Begins_FDA_Rolling_Submission_for_MCO-010_in_Retinitis_Pigmentosa\" >Nanoscope Therapeutics Begins FDA Rolling Submission for MCO-010 in Retinitis Pigmentosa<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera\/#FDA_Approves_Bayers_KERENDIA_for_Heart_Failure_With_Preserved_Ejection_Fraction\" >FDA Approves Bayer\u2019s KERENDIA for Heart Failure With Preserved Ejection Fraction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera\/#Klotho_Neurosciences_Receives_Orphan_Drug_Status_for_KLTO-202_in_Amyotrophic_Lateral_Sclerosis\" >Klotho Neurosciences Receives Orphan Drug Status for KLTO-202 in Amyotrophic Lateral Sclerosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera\/#Tretheras_TRE-515_Granted_FDA_Fast_Track_Designation_for_Metastatic_Prostate_Cancer\" >Trethera\u2019s TRE-515 Granted FDA Fast Track Designation for Metastatic Prostate Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera\/#Adcentrxs_ADRX-0405_Granted_FDA_Orphan_Drug_Designation_for_Gastric_Cancer\" >Adcentrx\u2019s ADRX-0405 Granted FDA Orphan Drug Designation for Gastric Cancer<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-nanoscope-therapeutics-begins-fda-rolling-submission-for-mco-010-in-retinitis-pigmentosa\"><span class=\"ez-toc-section\" id=\"Nanoscope_Therapeutics_Begins_FDA_Rolling_Submission_for_MCO-010_in_Retinitis_Pigmentosa\"><\/span>Nanoscope Therapeutics Begins FDA Rolling Submission for MCO-010 in Retinitis Pigmentosa<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Nanoscope Therapeutics<\/strong> has initiated a rolling submission of its <strong>Biologics License Application (BLA)<\/strong> to the FDA for <strong>MCO-010,<\/strong> a first-in-class, gene-agnostic optogenetic therapy targeting <strong>severe vision loss <\/strong>due to <a href=\"https:\/\/www.delveinsight.com\/report-store\/retinitis-pigmentosa-market\"><strong>retinitis pigmentosa (RP)<\/strong><\/a>. The therapy, delivered through a single, in-office intravitreal injection, is designed to restore vision in patients regardless of their underlying genetic mutation. Full submission of the BLA is expected by early 2026, and the application is eligible for priority review under the therapy\u2019s fast-track designation.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cFor the first time, patients who are considered to be on a path to permanent blindness may have a chance to regain sight,\u201d said Sulagna Bhattacharya, CEO and Co-Founder of Nanoscope. \u201cWe are deeply thankful to the FDA for their guidance as we remain steadfast in our mission to restore vision and bring light back into the lives of those living in darkness.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>MCO-010, based on Nanoscope\u2019s proprietary multi-characteristic opsin (MCO), reactivates surviving retinal cells by converting them into light-sensitive cells, bypassing dead photoreceptors. In the pivotal phase IIb RESTORE trial, MCO-010 met its primary endpoint, demonstrating visual acuity improvements of more than 0.3 LogMAR in both dose arms at 52 weeks. Notably, sustained vision gains have been observed through three years of follow-up, with no serious adverse events reported.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cBased on the preclinical science and evidence in clinical trials, MCO-010 represents a potential, important paradigm shift for patients and retina specialists,\u201d noted Dr. Allen C. Ho, Director of Retina Research at Wills Eye Hospital. \u201cThis therapy provides hope for meaningful improvement in the quality of life for the neediest retina patients of all.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>If approved, MCO-010 could become the first gene-agnostic treatment for inherited retinal disease, offering a new standard of care for over 100,000 individuals in the U.S. affected by RP.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-bayer-s-kerendia-for-heart-failure-with-preserved-ejection-fraction\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Bayers_KERENDIA_for_Heart_Failure_With_Preserved_Ejection_Fraction\"><\/span>FDA Approves Bayer\u2019s KERENDIA for Heart Failure With Preserved Ejection Fraction<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Bayer<\/strong> announced that the FDA has approved <strong>KERENDIA (finerenone)<\/strong> for the treatment of adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/heart-failure-market\"><strong>heart failure (HF)<\/strong><\/a><strong> <\/strong>with <strong>left ventricular ejection fraction (LVEF) \u226540%<\/strong>, marking a significant expansion of its indication. This approval, granted following a Priority Review of the supplemental New Drug Application, positions KERENDIA as the only FDA-approved non-steroidal mineralocorticoid receptor antagonist (nsMRA) for this patient population.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA\u2019s approval of finerenone expands treatment options for patients with heart failure with a left ventricular ejection fraction of \u226540% \u2013 a large and growing group of patients with a poor prognosis,\u201d said Dr. Scott D. Solomon, Professor of Medicine at Harvard Medical School and Chair of the FINEARTS-HF study executive committee. \u201cBased on the clinical efficacy we saw in the FINEARTS-HF study, finerenone can become a new pillar of comprehensive care.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The approval is based on results from the Phase III FINEARTS-HF trial, which demonstrated a 16% relative risk reduction in the composite primary endpoint of cardiovascular (CV) death and total HF events compared to placebo. The effect was consistent across all subgroups, including those with and without SGLT2 inhibitor use. With an estimated 3.7 million U.S. adults affected by HF with LVEF \u226540%, the approval addresses a high-risk population not adequately served by current therapies.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cEven with standard treatment, many patients with HF with preserved ejection fraction still face high risks of hospitalization or CV death,\u201d said Dr. Alanna Morris-Simon, Senior Medical Director, U.S. Medical Affairs at Bayer. \u201cNow, as a core pillar of treatment, KERENDIA can help reduce those risks and support better long-term outcomes.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-klotho-neurosciences-receives-orphan-drug-status-for-klto-202-in-amyotrophic-lateral-sclerosis\"><span class=\"ez-toc-section\" id=\"Klotho_Neurosciences_Receives_Orphan_Drug_Status_for_KLTO-202_in_Amyotrophic_Lateral_Sclerosis\"><\/span>Klotho Neurosciences Receives Orphan Drug Status for KLTO-202 in Amyotrophic Lateral Sclerosis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Klotho Neurosciences <\/strong>has announced that its lead gene therapy candidate, <strong>KLTO-202 (s-KL-AAV.myo)<\/strong>, has received<strong> Orphan Drug Designation (ODD)<\/strong> from the FDA for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/amyotrophic-lateral-sclerosis-als-market\" class=\"ek-link\"><strong>amyotrophic lateral sclerosis (ALS)<\/strong><\/a>. KLTO-202 is a novel gene and delivery system designed to express secreted Klotho protein (s-KL) and target neuromuscular junctions in motor neuron diseases, including ALS.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cReceiving the Orphan Drug Designation for s-KL-AAV.myo underscores the importance of bringing new treatment options to patients suffering from this rare, universally fatal disease,\u201d stated Dr. Joseph Sinkule, CEO of Klotho Neurosciences. \u201cWe aim to deliver the first gene replacement therapy addressing the neurologic insult and motor neuron degeneration associated with ALS.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The designation provides Klotho with several regulatory incentives, including seven years of U.S. market exclusivity, tax credits for clinical trials, and a waiver of FDA application fees. KLTO-202 is being developed for both ALS and muscular dystrophies, leveraging a desmin promoter to drive s-KL protein expression and targeting delivery to the neuromuscular junction.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Klotho has completed preclinical proof-of-concept studies in two ALS animal models and is preparing for large-scale manufacturing and regulatory meetings with the FDA and EMA to finalize its development path. \u201cAfter the FDA\u2019s review of the data leading to the Orphan Drug Designation, we believe this validates both our science and our approach to treating ALS,\u201d added Dr. Sinkule.<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-trethera-s-tre-515-granted-fda-fast-track-designation-for-metastatic-prostate-cancer\"><span class=\"ez-toc-section\" id=\"Tretheras_TRE-515_Granted_FDA_Fast_Track_Designation_for_Metastatic_Prostate_Cancer\"><\/span>Trethera\u2019s TRE-515 Granted FDA Fast Track Designation for Metastatic Prostate Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Trethera Corporation<\/strong> has announced that the FDA has granted <strong>Fast Track designation <\/strong>to its investigational therapy <strong>TRE-515<\/strong> in combination with <strong>radioligand therapy<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-castration-resistant-prostate-cancer-mcrpc-market\"><strong>PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)<\/strong><\/a>. TRE-515, currently being evaluated in a phase I clinical trial for solid tumors, is designed to enhance precision medicine by pairing with approved radiopharmaceuticals like PLUVICTO (lutetium Lu 177 vipivotide tetraxetan).<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis designation marks a critical milestone in our mission to develop more effective, well-tolerated therapies for aggressive and treatment-resistant prostate cancers,\u201d said Dr. Ken Schultz, Chairman and CEO of Trethera. \u201cBy combining TRE-515 with radioligand therapy, we aim to advance precision oncology and deliver long-term benefits to patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>TRE-515 is a novel first-in-class therapy targeting advanced prostate cancer that expresses prostate-specific membrane antigen (PSMA), a biomarker present in over 80% of prostate cancer cases. The FDA\u2019s decision was backed by promising data from Trethera\u2019s first-in-human phase I trial and encouraging preclinical results presented at the AACR Annual Meeting. The therapy has shown early antitumor activity and favorable tolerability, with no dose-limiting toxicities across 18-fold dose escalation.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe chemical structure of TRE-515 was designed for specific, on-target binding to create an optimal drug profile,\u201d said Dr. Michael Jung, UCLA Professor and cofounder of Trethera. \u201cI believe TRE-515 has the potential to make a meaningful difference in the lives of prostate cancer patients.\u201d Dr. Johannes Czernin, Trethera cofounder and Professor of Nuclear Medicine at UCLA, added, \u201cThe TRE-515 designation offers continued hope to the mCRPC community in need of new, precision-based treatment options.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-adcentrx-s-adrx-0405-granted-fda-orphan-drug-designation-for-gastric-cancer\"><span class=\"ez-toc-section\" id=\"Adcentrxs_ADRX-0405_Granted_FDA_Orphan_Drug_Designation_for_Gastric_Cancer\"><\/span>Adcentrx\u2019s ADRX-0405 Granted FDA Orphan Drug Designation for Gastric Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Adcentrx Therapeutics<\/strong> announced that the FDA has granted <strong>Orphan Drug Designation<\/strong> to <strong>ADRX-0405<\/strong>, a STEAP1-targeting <a href=\"https:\/\/www.delveinsight.com\/report-store\/antibody-drug-conjugate-market\"><strong>antibody-drug conjugate (ADC)<\/strong><\/a>, for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-market\"><strong>gastric cancer<\/strong><\/a><strong>.<\/strong> ADRX-0405 is currently being evaluated in the phase Ia portion of an ongoing phase Ia\/Ib clinical trial (NCT06710379) for advanced solid tumors, including metastatic castration-resistant prostate cancer, gastric cancer, and non-small cell lung cancer.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cReceiving orphan drug designation from the FDA is a notable milestone for Adcentrx and reinforces the potential for ADRX-0405 to improve the lives of patients with gastric cancer,\u201d said Hui Li, Ph.D., Founder and CEO of Adcentrx. \u201cWe are encouraged by the progress of our phase Ia trial and look forward to further evaluating the safety, tolerability, and anti-tumor activity of ADRX-0405.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Though STEAP1 is primarily associated with prostate cancer, its meaningful expression in gastric tumors opens the door for broader therapeutic potential. The FDA\u2019s orphan designation supports treatments for rare diseases affecting fewer than 200,000 people in the U.S., offering benefits such as tax credits, user fee waivers, and up to seven years of market exclusivity post-approval.<\/p>\n\n\n\n<p>Gastric cancer remains a challenging malignancy, often diagnosed at later stages. With over 30,000 new cases expected in the U.S. in 2025, ADRX-0405 offers a promising new approach for a population with significant unmet need.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nanoscope Therapeutics Begins FDA Rolling Submission for MCO-010 in Retinitis Pigmentosa Nanoscope Therapeutics has initiated a rolling submission of its Biologics License Application (BLA) to the FDA for MCO-010, a first-in-class, gene-agnostic optogenetic therapy targeting severe vision loss due to retinitis pigmentosa (RP). The therapy, delivered through a single, in-office intravitreal injection, is designed to [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":32806,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[74,19150,19151,16807,16808,77,78,204,704,16958,21323,635,20757,18861,18860,349,18946,18962,19174,420,639,498,22314,13055,11777,22212,11779,11863],"industry":[17225],"therapeutic_areas":[17242,17245,17228,17244],"class_list":["post-32805","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-amyotrophic-lateral-sclerosis","tag-amyotrophic-lateral-sclerosis-clinical-trials","tag-amyotrophic-lateral-sclerosis-emerging-drugs","tag-amyotrophic-lateral-sclerosis-market","tag-amyotrophic-lateral-sclerosis-pipeline","tag-antibody-drug-conjugate","tag-antibody-drug-conjugates","tag-delveinsight","tag-fda","tag-gastric-cancer","tag-gastric-cancers","tag-heart-failure","tag-heart-failure-drugs","tag-heart-failure-market","tag-heart-failure-therapies","tag-latest-pharma-news","tag-mcrpc","tag-metastatic-castration-resistant-prostate-cancer","tag-metastatic-castration-sensitive-prostate-cancer-market","tag-news","tag-pharma-news","tag-prostate-cancer","tag-prostate-cancer-drugs","tag-prostate-cancer-market","tag-retinitis-pigmentosa","tag-retinitis-pigmentosa-clinical-trials","tag-retinitis-pigmentosa-market","tag-retinitis-pigmentosa-pipeline-insight","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Bayer, Klotho, Trethera<\/title>\n<meta name=\"description\" content=\"Nanoscope\u2019s MCO-010; Bayer\u2019s KERENDIA; Klotho Neurosciences\u2019 KLTO-202; Trethera\u2019s TRE-515; Adcentrx\u2019s ADRX-0405\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Bayer, Klotho, Trethera\" \/>\n<meta property=\"og:description\" content=\"Nanoscope\u2019s MCO-010; Bayer\u2019s KERENDIA; Klotho Neurosciences\u2019 KLTO-202; Trethera\u2019s TRE-515; Adcentrx\u2019s ADRX-0405\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T11:35:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-15T11:35:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/15165451\/15-7-2025.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Bayer, Klotho, Trethera","description":"Nanoscope\u2019s MCO-010; Bayer\u2019s KERENDIA; Klotho Neurosciences\u2019 KLTO-202; Trethera\u2019s TRE-515; Adcentrx\u2019s ADRX-0405","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Bayer, Klotho, Trethera","og_description":"Nanoscope\u2019s MCO-010; Bayer\u2019s KERENDIA; Klotho Neurosciences\u2019 KLTO-202; Trethera\u2019s TRE-515; Adcentrx\u2019s ADRX-0405","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-07-15T11:35:56+00:00","article_modified_time":"2025-07-15T11:35:57+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/15165451\/15-7-2025.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera","name":"Pharma News | Bayer, Klotho, Trethera","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/15165451\/15-7-2025.png","datePublished":"2025-07-15T11:35:56+00:00","dateModified":"2025-07-15T11:35:57+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Nanoscope\u2019s MCO-010; Bayer\u2019s KERENDIA; Klotho Neurosciences\u2019 KLTO-202; Trethera\u2019s TRE-515; Adcentrx\u2019s ADRX-0405","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-bayer-klotho-trethera#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/15165451\/15-7-2025.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/15165451\/15-7-2025.png","width":772,"height":482,"caption":"pharma-news-for-bayer-klotho-trethera"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/15165451\/15-7-2025-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">amyotrophic lateral sclerosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amyotrophic Lateral Sclerosis clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amyotrophic Lateral Sclerosis emerging drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amyotrophic lateral sclerosis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amyotrophic lateral sclerosis pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugate<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gastric cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gastric Cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Heart failure<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">heart failure drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Heart Failure Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Heart Failure Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">mCRPC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">metastatic castration-resistant prostate cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">metastatic castration-sensitive prostate cancer market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prostate Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prostate Cancer Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prostate Cancer Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinitis Pigmentosa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinitis Pigmentosa Clinical Trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinitis Pigmentosa Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinitis Pigmentosa pipeline insight<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">amyotrophic lateral sclerosis<\/span>","<span class=\"advgb-post-tax-term\">Amyotrophic Lateral Sclerosis clinical trials<\/span>","<span class=\"advgb-post-tax-term\">Amyotrophic Lateral Sclerosis emerging drugs<\/span>","<span class=\"advgb-post-tax-term\">Amyotrophic lateral sclerosis market<\/span>","<span class=\"advgb-post-tax-term\">Amyotrophic lateral sclerosis pipeline<\/span>","<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugate<\/span>","<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Gastric cancer<\/span>","<span class=\"advgb-post-tax-term\">Gastric Cancers<\/span>","<span class=\"advgb-post-tax-term\">Heart failure<\/span>","<span class=\"advgb-post-tax-term\">heart failure drugs<\/span>","<span class=\"advgb-post-tax-term\">Heart Failure Market<\/span>","<span class=\"advgb-post-tax-term\">Heart Failure Therapies<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">mCRPC<\/span>","<span class=\"advgb-post-tax-term\">metastatic castration-resistant prostate cancer<\/span>","<span class=\"advgb-post-tax-term\">metastatic castration-sensitive prostate cancer market<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer Drugs<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer Market<\/span>","<span class=\"advgb-post-tax-term\">Retinitis Pigmentosa<\/span>","<span class=\"advgb-post-tax-term\">Retinitis Pigmentosa Clinical Trials<\/span>","<span class=\"advgb-post-tax-term\">Retinitis Pigmentosa Market<\/span>","<span class=\"advgb-post-tax-term\">Retinitis Pigmentosa pipeline insight<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 months ago","modified":"Updated 9 months ago"},"absolute_dates":{"created":"Posted on Jul 15, 2025","modified":"Updated on Jul 15, 2025"},"absolute_dates_time":{"created":"Posted on Jul 15, 2025 5:05 pm","modified":"Updated on Jul 15, 2025 5:05 pm"},"featured_img_caption":"pharma-news-for-bayer-klotho-trethera\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32805"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32805\/revisions"}],"predecessor-version":[{"id":32807,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32805\/revisions\/32807"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32806"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32805"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32805"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32805"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32805"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}